These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11550931)

  • 1. Errors-in-variables in joint population pharmacokinetic/pharmacodynamic modeling.
    Bennett J; Wakefield J
    Biometrics; 2001 Sep; 57(3):803-12. PubMed ID: 11550931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of CTB-001, a Recently Developed Generic of Bivalirudin.
    Han S; Kim YH; Choi HY; Kim MJ; Kim WJ; Park H; Bae KS; Lim HS
    Pharm Res; 2019 Aug; 36(10):146. PubMed ID: 31396727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian approach for PK/PD modeling with PD data below limit of quantification.
    Zhou H; Hartford A; Tsai K
    J Biopharm Stat; 2012; 22(6):1220-43. PubMed ID: 23075019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical methods for population pharmacokinetic modelling.
    Racine-Poon A; Wakefield J
    Stat Methods Med Res; 1998 Mar; 7(1):63-84. PubMed ID: 9533262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing convergence of Markov chain Monte Carlo simulations in hierarchical Bayesian models for population pharmacokinetics.
    Dodds MG; Vicini P
    Ann Biomed Eng; 2004 Sep; 32(9):1300-13. PubMed ID: 15493516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation.
    Wakefield J; Racine-Poon A
    Stat Med; 1995 May 15-30; 14(9-10):971-86. PubMed ID: 7569514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacology of recombinant hirudin, a new anticoagulant.
    Meyer BH; Luus HG; Müller FO; Badenhorst PN; Röthig HJ
    S Afr Med J; 1990 Sep; 78(5):268-70. PubMed ID: 2392724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian analysis of physiologically based toxicokinetic and toxicodynamic models.
    Hack CE
    Toxicology; 2006 Apr; 221(2-3):241-8. PubMed ID: 16466842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bayesian population PK-PD model of ispinesib-induced myelosuppression.
    Kathman SJ; Williams DH; Hodge JP; Dar M
    Clin Pharmacol Ther; 2007 Jan; 81(1):88-94. PubMed ID: 17186004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of population pharmacokinetic studies.
    Wakefield J; Rahman N
    Biometrics; 2000 Mar; 56(1):263-70. PubMed ID: 10783805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.
    Proost JH; Schiere S; Eleveld DJ; Wierda JM
    Biopharm Drug Dispos; 2007 Nov; 28(8):455-73. PubMed ID: 17847121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
    Zhang L; Beal SL; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):387-404. PubMed ID: 15000421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance comparison of first-order conditional estimation with interaction and Bayesian estimation methods for estimating the population parameters and its distribution from data sets with a low number of subjects.
    Pradhan S; Song B; Lee J; Chae JW; Kim KI; Back HM; Han N; Kwon KI; Yun HY
    BMC Med Res Methodol; 2017 Dec; 17(1):154. PubMed ID: 29191177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rational estimation of drug dosage through pharmacometric modeling: The case of a long-acting depot antipsychotic].
    Simon N; Azorin JM
    Encephale; 2015 Apr; 41(2):159-67. PubMed ID: 25765186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans.
    Fox I; Dawson A; Loynds P; Eisner J; Findlen K; Levin E; Hanson D; Mant T; Wagner J; Maraganore J
    Thromb Haemost; 1993 Feb; 69(2):157-63. PubMed ID: 8456428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The application of a Bayesian approach to the analysis of a complex, mechanistically based model.
    Jonsson F; Jonsson EN; Bois FY; Marshall S
    J Biopharm Stat; 2007; 17(1):65-92. PubMed ID: 17219756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
    Fabre MA; Fuseau E; Ficheux H
    J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.
    Derendorf H; Meibohm B
    Pharm Res; 1999 Feb; 16(2):176-85. PubMed ID: 10100300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.